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Edited by Varda RotterAbstract Although it has been shown that phosphorylations of
p53 serine its residues are critical events for the regulation of
their function, the speciﬁc biological eﬀects of each of these
phosphorylations, especially at serine 392, remain to be eluci-
dated. Serine 392 has been proposed to play a role in the
tetramerization of p53 and in the enhancement of its DNA-
binding aﬃnity. However, this is not consistent with other
reports showing that substitution of serine 392 does not disrupt
p53 function. These discrepancies suggest that modiﬁcation of
serine 392 may contribute to p53 activity through other
transactivating pathways. In this study, we demonstrate that
this C-terminal serine residue (p53-392S) in fact plays a critical
role in the regulation of p53 stability such that substitution with
alanine (p53-392A) strongly enhances p53 stability without
disrupting mouse double minute 2 binding. Additionally, the p53-
392A mutant is localized mainly in the nucleus, whereas both
wild-type p53 and a glutamic acid mutant, p53-392E, are evenly
distributed throughout the cytoplasm and nucleus. However,
each of these p53 species had similar eﬀects on both cell cycle
inhibition and apoptosis, in response to either UV or adriamycin
treatment. Moreover, p53-392A protein was resistant to E6-
mediated degradation. Our results suggest that although serine
392 is not essential for the transactivation and nuclear import of
p53, it exerts important eﬀects upon p53 stability via the
inhibition of its nuclear export mechanism.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The p53 tumor suppressor protein is a crucial component of
cellular mechanisms that are initiated by a variety of cellular
stresses [1,2]. Under normal conditions, p53 is a short-lived
protein that is highly regulated and maintained at low or un-
detectable levels. However, in response to genotoxic stress or
oncogenic signaling, p53 levels rapidly increase, mainly* Corresponding author. Fax: +82-2-388-0924.
E-mail address: parksi@nih.go.kr (S.-I. Park).
Abbreviations: Adr, adriamycin; CHX, cycloheximide; PBS, phos-
phate-buﬀered saline; WB, Western blot; WT, wild-type; MDM2,
mouse double minute 2
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doi:10.1016/j.febslet.2004.07.014through protein stabilization [3]. Recent ﬁndings suggest that
p53 stabilization and accumulation can occur via the inhibition
of nuclear export, implicating nuclear import–export as a po-
tential mechanism for controlling p53 stability [4]. The levels
and activity of p53 are controlled largely by mouse double
minute 2 (MDM2), which is ampliﬁed or overexpressed in a
variety of human tumors and can function as an oncogene in
tissue culture systems [5,6]. MDM2 can bind directly to p53
and promote its ubiquitination and subsequently its degrada-
tion by the proteasome [6,7]. The ability of MDM2 to degrade
p53 depends on both its ubiquitin E3 ligase activity and its
nuclear localization signal (NLS) and nuclear export signal,
which are required for MDM2 to shuttle between the nucleus
and the cytoplasm [5,6].
The induction of p53 involves several mechanisms including
post-translational modiﬁcation such as phosphorylation and
acetylation [8]. DNA-damage-induced phosphorylation of se-
rines and threonines within the p53 amino terminus contrib-
utes to p53 stability by preventing MDM2 from binding and
by rendering p53 more resistant to MDM2 [9–11]. Five serine
residues in the carboxy-terminal region, and seven serines and
one threonine within the N-terminal 46 residues, are known to
be inducibly phosphorylated [12], but the exact order of
phosphorylation and their individual contributions to p53 ef-
fector function still remain to be elucidated. For example,
serine residues at positions 6, 9, 15, 20 and 37 are phosphor-
ylated in response to DNA damage, probably by various
protein kinases including ATM, Chk2, DNA-PK and ATR
[13–15]. Phosphorylation of Ser 15 is observed only in response
to DNA damage [16], but not following p53 activation in re-
sponse to E1A expression [17], indicating that the speciﬁc roles
of individual phosphorylation sites depend on the speciﬁc
stimulus and also probably the cell type. In addition, phos-
phorylation of Ser 46 is functionally important, because mu-
tation of this site within the p53 protein decreases the
sensitivity towards UV-induced apoptosis [18,19]. There are at
least three phosphorylation sites near the C-terminus of human
p53 at positions 315, 378 and 392. Ser 315 has been shown to
be a target of both p34cdc2 kinase and cyclin-dependent kinase
2 (cdk2) [20]. Ser 392 is phosphorylated in vitro by puriﬁed
casein kinase II and Ser 378 is a site for phosphorylation by
protein kinase C (PKC). Furthermore, phosphorylation of
these C-terminal serines has been shown to enhance the in
vitro speciﬁc DNA-binding activity of p53 [21].blished by Elsevier B.V. All rights reserved.
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tially regulated by the substitution of serine 392 but that this
mutation does not aﬀect either p53-induced cell cycle inhibi-
tion or apoptosis. The increase in p53 stability was also found
to be independent of MDM2 activity and the modiﬁcation of
serine 392 also confers resistance to E6-mediated p53 degra-
dation. We suggest, therefore, that the regulation of p53 sta-
bility by modiﬁcation of its serine 392 residue is due to the
dysregulation of the nuclear export mechanism.2. Materials and methods
2.1. Cell culture and reagents
The human prostate cancer cell line, PC3, was obtained from ATCC
and maintained in RPMI-1640, supplemented with 10% heat inacti-
vated fetal bovine serum (Gibco BRL), at 37 C in a humidiﬁed
chamber with 5% CO2. All of the reagents used in these experiments
were purchased from Sigma–Aldrich and antibodies were obtained
from Santa Cruz Biotech.
2.2. Construction of vectors and transfectiom
p53 wild-type (WT), 392A and 392E constructs were generated by
RT-PCR based cloning using the pcDNA 3.1 topo His/V5 vector
(Invitrogen). The primers used are shown in Table 1. The HPV-6
clone was kindly provided by S.G. Chi (Kyung Hee University,
Seoul). The transfection reagent used was Gemeporter, which was
purchased from Gene Therapy Systems. Transfection procedures were
performed following the manufacturer’s protocol. Brieﬂy, cells were
seeded in 6 well plates at a concentration of 1 105 cells/well. 4 lg of
DNA per well was mixed with serum-free media containing Gene-
porter (10 ll/well), incubated for 30 min at room temperature, and
added to cells that were previously washed twice with phosphate-
buﬀered saline (PBS). After 3–5 h, media (1 ml/well) containing 20%
FBS were added to each well. All experiments, including thymidine
incorporation assays, Western blotting, immunoprecipitations
and cell death assays were performed after incubation for 24 h.
To monitor transfection eﬃciency, cells were co-transfected with
GFP-pcDNA.
2.3. Cell proliferation and DNA synthesis assays
Cells were seeded at a concentration of 1 104 cells/well in 24 well
plates and transfected with p53 constructs on the following day. The
cells were then washed twice with PBS, followed by the addition of
medium containing 0.1 lg/ml adriamycin (Adr) or 5 ng/ml actinomycin
D, and incubated for 20 h. Cells were then pulse-labeled for 4 h with
[3H]thymidine, which was added to the cells at a ﬁnal concentration of
1 lCi/ ml. Cells were then washed with PBS twice and incubated with
70% TCA at 4 C for 0.5 h to precipitate nucleic acids. After two
additional washes with PBS, precipitates were dissolved with DNA
lysis buﬀer (2% Na2C03, 2% SDS, and 0.1% NP-40) and mixed with 2
volumes of scintillation Cocktail solution to measure the levels of in-
corporated isotope using the liquid b-counter. To examine the eﬀect of
UV, cells were harvested after 20 h of 100 J/m2 UV exposure and
subjected to the same procedure as described above. Each experiment
was performed in triplicate.Table 1
Sequences of the primers used in this study
Name Sequence (50–30
p53-wt-l S CATGGAGGAGC
p53-wt-2 AS GTCTGAGTCAG
p53-S392A AS GTCTGCGTCAG
p53-S392E AS GTCCTCGTCAG
p53-AS AS CAAGTCACAGA
GAPDH-1 S AACCATGAGAA
GAPDH-2 AS CATGTGGGCCA
T7 TAATACGACTC
S and AS indicate the orientation of sense and antisense primers, respectively
ChIP, respectively. All sequences are oriented in the 50 to 30 direction.2.4. Indirect immunoﬂuorescent analysis of p53
To determine the localization of p53, we transfected PC3 cells with
either WT p53, p53-392A or p53-392E that had been V5-His-tagged
for 24 h. In addition, to examine resistance to E6-mediated p53 deg-
radation, cells were co-transfected with each p53 construct and an E6
construct. Following transfection, the cells were either incubated with
Adr or exposed to UV, and then ﬁxed with 2% paraformaldehyde for 2
h at RT, followed by incubation with both permeable and blocking
buﬀers. The cells were then incubated with anti-V5 antibody, diluted in
permeable buﬀer (1:2000) for 2 h at RT and subsequently treated with
anti-mouse IgG-Rhodamine for 2 h. The antibody incubations were
followed by staining with DAPI for 10 min and the cells were then
washed twice with ice cold PBS and examined under ﬂuorescence
microscopy.
2.5. Apoptosis assays
Cells were seeded (4 105 cells/well) in 96 well plates and incubated
with 10 lM BrdU labeling solution (Cellular DNA Fragmentation
ELISA kit, Roche) at 37 C for 24 h. After the ﬁrst incubation, cells
were either treated with Adr or UV irradiated at 37 C for 6 h prior to
harvesting. Cells were lysed in incubation solution and were then in-
cubated in precoated plates with anti-BrdU POD-conjugate solution
according to the manufacturer’s guidelines. These experiments were
repeated at least three times. The absorbance level of each sample was
measured by an ELISA microplate reader.
2.6. Real-Time PCR
Real-time PCRs were performed using a TaqMan detection system,
consisting of 12.5 ll of TaqMan Universal PCRMasler Mix, 1.25 ll of
Assay-on-Demand Gene Expression probe (Applied Biosystems,
USA), TaqMan probe, 100 ng of each cDNA template and water, in a
ﬁnal volume of 25 ll. All PCR samples and controls were prepared in
identical tubes in triplicate using 0.2 ml Micro-Amp Optical reaction
tubes and MicroAmp Optical tube caps (Applied Biosystems, USA).
Each PCR mixture was held at 50 C for 5 min and denatured at 95 C
for 10 min. 40 ampliﬁcation cycles were carried out at 95 C for 20 s
followed by 60 C for 1 min. All PCRs were performed using an ABI
PRISM 7900HT (Applied Biosystems) and PCR products were an-
alyzed using the corresponding sequence detector software (Applied
Biosystems).
2.7. TUNEL assay
To detect DNA breaks in apoptotic cells in situ, we adopted a ter-
minal deoxynucleotidyl transferase (TdT)-mediuted DIG-nucleotide
Nick end labeling (TUNEL) method using a Cell Death Detection Kit,
TMR-Red (Roche, Germany). Negative controls were prepared by
omitting TdT and DNase-treated cells were used as positive controls.
TUNEL ﬂuorescence of individual nuclei, in a ﬁnal volume of 700 ll,
was analyzed by an FACS Calibur (Becton–Dickinson, USA), while
gating on physical parameters was enacted to exclude cell debris. A
minimum of 10 000 events was counted per sample.3. Results
3.1. Substitution of serine 392 alters p53 stability
To study the functional role of the p53 serine residue at
position 392, we generated two diﬀerent p53 mutant constructs) Usage
CGCAGTCAG C
GCCCTTCTG C
GCCCTTCTG C
GCCCTTCTG C
CTTGSGCTGTCC Q
GTATGACAACAGC Q
TGAGGTCCACCAC Q
ACTATAGGG C and Q
. Q and C represent their usage in semi-quantitative gene cloning and
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(p53-392E). To examine the pattern of expression of these
constructs, the p53-null cell line PC3 was transiently trans-
fected with normalized levels of either WT p53, p53-392A,
p53-392E or appropriate control vectors. We were able to
speciﬁcally detect and quantify exogenous p53 mRNA levels
using real-tune PCR, all of which were normalized to GAPDH
mRNA expression, and found them to be comparable
(Fig. 1A). The p53-392A protein levels, however, were higher
than either WT p53 or p53-392E under the same experimental
conditions (Fig. 1B). These results indicate that the C-terminal
serine residue of p53 has an important role in the regulation of
p53 stability. To explore the molecular mechanism by which
serine 392 aﬀects p53 stability, we tested whether the replace-
ment of this residue directly controls p53-mediated cell cycle
inhibition and apoptosis.Fig. 1. Modiﬁcation of serine 392 aﬀects the stability of p53. (A) PC3
cells were transfected with either a control pcDNA vector or the in-
dicated p53 constructs (4 lg). To ensure comparable transfection ef-
ﬁciencies, a sample of the cells was transfected with GFP and
monitored for expression levels. PC3 cells transfected with the p53
constructs were analyzed by real time-PCR and p53 levels were nor-
malized to GAPDH. Data shown are the average of two assays. Error
bars, SEM. (B) A fraction of PCS cells from the experiment described
in (A) was lysed and tested by Western blotting for p53 expression.
b-actin was usied as a loading control.3.2. Substitution of p53 serine 392 does not disrupt either
UV- or Adr-induced cell cycle inhibition and apoptosis
To examine the impact of our p53 mutants on p53-mediated
cell cycle inhibition, we determined the impact of each trans-
fected construct upon cell cycle regulation in response to Adr
(0.2 lg/ml) using a [3H]thymidine incorporation assay fol-
lowing transient transfection. The p53 variants did not show
signiﬁcant diﬀerences in their eﬀects upon cell cycle regulation,
with inhibition ranging from 40% to 60% of the control
(Fig. 2A). Next, we examined Adr-induced apoptosis using
both DNA-fragmentation and TUNEL assays and again
found no signiﬁcant diﬀerences between the 3 p53 species
(Fig. 2B). These results suggest that Ser-392 does not play a
role in Adr-induced cell cycle inhibition and apoptosis. Pa-
rental PC3 cells were resistant to apoptosis, therefore Adr-in-
duced apoptosis and cell cycle inhibition are mediated by p53
(Fig. 2A and B). We then examined whether these p53 variants
show any discrepancies in their ability to mediate UV-induced
apoptosis or cell cycle inhibition. Under the same Adr-induced
apoptotic conditions, transfectants were exposed to 100 J/m2
UV amd cell cycle inhibition and apoptosis levels were deter-
mined using the same method. UV irradiation was found to
have an eﬀect upon p53-induced cell cycle arrest and apoptosis
but this did not vary between the diﬀerent transfected p53
species (Fig. 2C and D). These results demonstrate that neither
UV-induced cell cycle arrest nor apoptosis are regulated by
modiﬁcation of p53 serine 392, although UV exposure is
known to cause phosphorylation of this residue [23]. The role
of serine 392 is, therefore, likely to be the maintenance of p53
stability but this is not related to the induction of either ap-
optosis or cell Cycle inhibition. Additionally, these results are
also consistent with a previous study showing that replacement
of serine 392 does not disrupt p53 function [24].
3.3. p53 Ser-392 mutants have similar MDM2 binding aﬃnities
To investigate whether MDM2 is required for the observed
increases in p53 stability, we checked the interaction between
each p53 Ser-392 mutant and MDM2. MDM2 is known to
promote the downregulation of p53 through nuclear export
and ubiquitin-dependent degradation [25,26]. Cell extracts
from PC3 cells, expressing exogenous p53 mutants, were im-
munoprecipitated wilh MDM2 and subsequent Western blot
analysis revealed that the binding aﬃnity between each of the
p53 mutants and MDM2 showed no signiﬁcant diﬀerences
(Fig. 3A). These results indicate that the enhanced stability of
p53-392A occurs independently of MDM2 binding in vitro.
We next examined the possibility that this increased p53 sta-
bility is due to a prolonged mRNA half life. Cells were
transfected with p53 variants and treated with a high dose (2
mM) of the transcription inhibitor actinomycin D [27] over a
speciﬁc tune course. As shown in Fig. 3B, each of the exoge-
nous p53 transcript levels was reduced over time and did not
show any signiﬁcant diﬀerences in stability. Furthermore, the
same experiments were also performed with an inhibitor of
translation, cycloheximide (CHX) [28]. Similar results were
obtained with the exception of p53-392A levels (Fig. 3C).
Strikingly, we found that the steady-state levels of p53-392A
were unchanged up to the 8 h timepoint, indicating that the
modiﬁcation of Ser-392 is a critical post-translational regula-
tory mechanism of p53. Our ﬁndings, therefore, indicate that
the modiﬁcation of Ser-392 regulates p53 stability through a
post-translational mechanism that is independent of MDM2
Fig. 2. Cells expressing exogenous WT, 392A and 392E p53 proteins show the same susceptibility to both UV- and Adr-induced apoptosis and cel
cycle inhibition. (A) PC3 cells were transfected with pcDNA control and WT, 392A and 392E p53 constructs cells were either left untreated (ﬁlled
column) or treated with Adr (Adr) (0.2 lg/ml, open column). Cell cycle regulation was quantiﬁed 24 h later by [3H]thymidine incorporation; results
shown are the means ± S.D. The numbers above the bar indicate percentage suppression. (B) Apoptosis, measured under the same cell cycle reg-
ulatory conditions, was quantiﬁed using both the DNA fragmentation and TUNEL assay methods (M, TUNEL positive). (C) PC3 cells were either
left untreated or irradiated with UV (100 J/m2) to induce apoptosis and analyzed 20 h later. The numbers on the bar indicate the percentage of
apoptotic cells, when compared with the control. (D) UV-induced apoptosis was quantiﬁed by both DNA fragmentation and TUNEL assays.
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Fig. 4. p53-392A mutants are resistant to E6-mediated degradation.
HPV protein E6 was co-expressed with WT, 3 92A and 392E p53
constructs in PC3 cells. (A) Cell lysates were analyzed by Western
blotting for exogenous p53 stability. (B) Cells were either left untreated
(ﬁlled column) or treated with a UV dose (100 J/m2). Cell cycle reg-
ulation was quantiﬁed 24 h later by [3H]thymidine incorporation; re-
sults are means ± S.D. under the same conditions as shown in Fig. 2.
Fig. 3. Modiﬁcation of serine 392 does not disrupt the interaction
between MDM2 and p53. (A) PC3 cells were transfected with the WT,
392A and 392E p53 constructs and cells were harvested after 48 h. Cell
lysates were immunoprecipitated with anti-MDM2 antibodies and co-
precipitated exogenous p53 protein was then detected by Western
blotting. The WBs were also tested using anti-MDM2 antibodies as a
loading control. (B) PC3 cells were transfected with the same p53
constructs, the expression of which was measured by RT-PCR after
treatment with actinomycin D at 0, 1.2 and 24 h. The GAPDH nor-
malizing conlrol transcript levels also decreased over the same time
course. (C) PC3 cells were transﬁicted with p53 constructs and the cells
were harvested after 0, 4 and 8 h treatment with CHX. Cell lysates
were analyzed by Western blotting with V5 antibodies to measure the
stability of the exogenous p53 expression. b-Actin was used as a
loading control.
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Ser-392 blocks the nuclear export of p53, as this is essential for
proteasome-mediated degradation via MDM2 [5].
3.4. p53-392A protein is resistant to E6-mediated degradation
To examine the possible role of serine 392 in p53 nuclear
export, we transiently co-transfected PC3 cells with HPV-E6
and each of the p53 Ser-392 mutants, as the mechanism of
E6-induced p53 degradation is similar to MDM2 [29–31]. We
predicted, therefore, that if p53 nuclear export is disrupted by
modiﬁcation of Ser-392, this should also aﬀect E6-induced
p53 destruction. Interestingly, p53-392A protein was found to
be resistant to E6-mediated destruction, whereas both WT
p53 and p53-392E proteins were degraded (Fig. 4A). To
further explore the functional relationship between p53-392A
and E6, we tested the eﬀects of E6 expression on the cell
cycle. As shown in Fig. 4B, p53-392A transfected cells are
susceptible to cell cycle inhibition, whereas both WT p53 and
p53-392E transfected PC3 cells showed no comparable cell
cycle block under the same conditions. These results
strongly suggested that modiﬁcation of serine 392 inhibits
E6-mediated p53 degradation by regulating its subcellular
localization.3.5. p53-392A is localized in the nucleus
Based on our observations that p53 is likely to be stabilized
by blocking nuclear export, we investigated this directly by
determining whether the modiﬁcation of Ser-392 directly
promotes cytoplaismic retention of p53. As indicated in Fig. 5,
ectopic expression of p53-392A yields a predominantly nuclear
stain, with less than 5% of cells showing clear cytoplasmic
localization. In contrast, however, WT p53 was distributed
diﬀusely throughout the cell and p53-392E was sequestered in
the cytoplasm. These results raise the possibility that modiﬁ-
cation of Ser-392 regulates both the nuclear localization and
nuclear export of p53. According to previous reports, p53
contains a NLS in its C-terminus, whereas nuclear export is
accomplished through the MDM2 pathway [31,32]. Although
our previous results indicate that modiﬁcation of Ser-392 does
not aﬀect p53-mediated functions, we cannot exclude the
possibility that this modiﬁcation is required for localization of
p53 in the nucleus.
To further evaluate the role of Ser-392 in p53 nuclear lo-
calization, we transiently transfected PC3 cells with our p53
constructs. As expected, indirect immunoﬂuorescent analysis
showed that p53 accumulates in the nucleus, regardless of
serine 392 mutations, at 1 h, but that each p53 species had a
diﬀerent subcellular localization after 12 h. In contrast to WT
p53 and p53-392E, which showed a dispersed localization, a
large portion of exogenously expressed p53-392A was detected
in the nucleus (data are not shown). This ﬁnding was consis-
Fig. 5. p53 serine 392 mutants show diﬀerent cellular distributions. PC3 cells were transfected with WT, 392A and 392E p53 constructs and the
localization of p53 was detected by indirect immunoﬂuorescence using anti-V5 antibody and rhodamine conjugated mouse IgG. Nuclear DNA was
counterstained with DAPI (blue). Areas of p53 localization are indicated by arrowheads.
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degradation. Finally, we examined the subcellular localization
of p53 after co-transfection with E6 and determined that p53-
392A was resistant to E6-mediated nuclear export.4. Discussion
We propose that the serine residue at position 392 in the p53
protein functions as a regulator of p53 nuclear export and that
it is critically involved in the regulation of p53 subcellular lo-
calization. The nuclear localization of p53 is essential for its
role as a transcription factor in tumor suppression. Moreover,
phosphorylation of serine 392 has been proposed as the reg-
ulating motif of p53 tetramerization, leading to enhancement
of target gene expression [23,33]. However, this hypothesis is
not consistent with other results showing that IR-induced p53
activation initiates both apoptosis and cell cycle arrest in the
absence of any Ser-392 modiﬁcation, accompanied by the
transcriptional induction of p53 target genes such as p21/waﬂ
and Bax. In addition, modiﬁcation of Ser-392 does not aﬀect
either Adr or UV-induced cell cycle arrest and apoptosis [22]
(Fig. 2), which is induced via the upregulation of p53 target
genes. Moreover, we tested the transcriptional variation of
each of our WT, 392A and 392E p53 constructs and no sig-
niﬁcant diﬀerences were detected (data not shown). In con-
trast, we showed that the modiﬁcation of Ser-392 is required to
maintain the localization of p53 in the nucleus. Hence, the
regulation of p53 nuclear export by modiﬁcation of Ser-392
has an important role in the control of p53 function, in addi-
tion to its role in p53 tetramerization.
The eﬀects of the modiﬁcation of p53 serine 392 are not
necessarily related to its charge, such as is the case with the N-
terminal nuclear export mechanisms [34], as both serine to al-
anine substitutions and the phosphorylation of Ser-392 were
found to increase p53 stability [23,33]. Moreover, modiﬁcationof Ser-392 regulates both p53 nuclear export and protein sta-
bility. Using several lines of investigation, therefore, our studies
indicate that the modiﬁcation of Ser-392 increases p53 protein
stability through its retention in the nucleus. Although we have
not yet fully elucidated the nuclear export mechanism of p53,
our results suggest the eistence of a newp53 regulatory pathway.
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